North Water Trends | Beishui's net purchase of 453 million Cinda Biotech (01801) surged after the performance, Beishui Fenggao sold over HK$500 million

The Zhitong Finance App learned that on August 26, in the Hong Kong stock market, Beishui traded a net purchase of HK$453 million. Among them, Hong Kong Stock Connect (Shanghai) had net sales of HK$1,125 million and Hong Kong Stock Connect (Shenzhen) had net purchases of HK$1,577 billion.

The individual stocks that Beishui Net bought the most were Alibaba-W (09988), Changfei Optical Cable (06869), and SMIC (00981). The individual stocks sold the most by Beishui Net were Cinda Biotech (01801), Tencent (00700), and Cambridge Technology (06166).

Hong Kong Stock Connect (Shanghai) active trading stocks

Hong Kong Stock Connect (Shenzhen) active trading stocks

Alibaba-W (09988) received a net purchase of HK$1,212 billion. On August 23, Ali announced a HK$80 billion IPO, and all of the funds raised will be invested in AI and related infrastructure construction. On August 25, according to sources, Alibaba founder Ma Yun increased his holdings of Alibaba's Hong Kong shares for several days, with a total investment of more than 600 million Hong Kong dollars. So far, Ma Yun and Ali's management have recently increased their total holdings by more than HK$800 million.

Changfei Optical Fiber Cable (06869) received a net purchase of HK$1,034 million. According to a report published by HSBC Research, Changfei Optical Cable's second-quarter revenue fell short of expectations, but both gross margin and net profit were higher than the bank's and market forecasts. Net profit for the period surged 12.8 times year-on-year to RMB 2,339 billion, close to the upper limit of the previous profit forecast of between RMB 1.9 billion and RMB 2.5 billion, reflecting that the product portfolio was upgraded faster than expected.

SMIC (00981) and Huahong Hongli (01347) received net purchases of HK$717 million and HK$22.26 million respectively. SMIC's 26Q2 wafer business achieved a sharp rise in volume and price, with revenue, net profit, and revenue in various sectors increasing month-on-month, and gross margin continued to rise. At the same time, the company gave optimistic guidance that revenue and gross margin continued to rise in the third quarter; Huahong Hongli 26Q2's revenue in a single quarter hit a record high, with a capacity utilization rate of 102.8%. The full production state confirms that demand for downstream chip orders is hot.

Jiantao Laminate (01888) received a net purchase of HK$166 million. The company said that entering the second half of 2026, the shortage of electronic glass fiber cloth became more serious, and the price of copper-clad sheets and upstream materials continued to soar. The company's profit in July 2026 was about HK$1.1 billion, a record high in a single month. Citi said it raised its 2026-2028 profit forecast by 9%-10% and raised the target price to HK$95, given that the company's profit level in July was slightly stronger than expected.

CNOOC (00883) had a net sale of HK$146 million. Market concerns about the Middle East geopolitical conflict have abated, and international oil prices have dropped significantly this week. In addition, CNOOC announced post-market results. Net profit for the first half of the year was 85.8 billion yuan, up 23.4% year on year; the interim dividend was HK$0.94 per share, up 28.8% year on year. CNOOC said net production in the first half of the year was 398.7 hundred barrels of oil equivalent, up 3.7% year on year.

Cinda Biotech (01801) surged 9% after the results. Some of Beishui's capital was sold at high prices, with a net sales volume of HK$521 million throughout the day. Cinda Biotech announced interim results. The IFRS net profit for the first half of 2026 reached 1.3 billion yuan, an increase of 50.2% over the previous year, exceeding the full year level of 2025. “The total amount of overseas BD cooperation in the past 10 months reached 34 billion US dollars, accounting for more than 30% of the total external licensing of Chinese pharmaceutical companies during the same period.

In addition, Pharmaceutical Biotech (02269) received a net purchase of HK$537 million. Meanwhile, Tencent (00700) and Cambridge Technology (06166) were net sold at HK$337 million and HK$149 million respectively.